Comments on recent advances and recommendations for the assessment of autoantibodies to cellular antigens referred as antinuclear antibodies

Annals of the Rheumatic Diseases

Volumn 73, Issue 7, 2014, Pages

  Mahler, Michael ^a   Dervieux, Thierry ^b  

^a INOVA DIAGNOSTICS INC   (United States)

^b Exagen Diagnostics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICITRULLINATED PROTEIN ANTIBODY; ANTINUCLEAR ANTIBODY; CELL ANTIBODY; CELL ANTIGEN; CELL NUCLEUS ANTIGEN; EXTRACTABLE NUCLEAR ANTIGEN; PROTEIN ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ASSAY; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE; LETTER; MYOSITIS; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SJOEGREN SYNDROME; SOLID PHASE ASSAY; SOLID PHASE IMMUNOASSAY; STANDARDIZATION; SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; WEGENER GRANULOMATOSIS;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; SYSTEMIC LUPUS ERYTHEMATOSUS;

ALLERGY AND IMMUNOLOGY; ANTIBODIES, ANTINUCLEAR; AUTOANTIGENS; HUMANS; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 84902275786     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205324     Document Type: Letter

References (26)

1. Agmon-Levin N, Damoiseaux J, Kallenberg C, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2014;73:17-23.
2. Bossuyt X, Fieuws S. Detection of antinuclear antibodies: Added value of solid phase assay? Ann Rheum Dis 2014;73:e10.
3. Abeles AM, Abeles M. The clinical utility of a positive antinuclear antibody test result. Am J Med 2013;126:342-8.
4. Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR scleroderma trials and research group database. Ann Rheum Dis 2007;66:754-63. (Pubitemid 46846694)
5. Mahler M, Fritzler MJ. The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin Dev Immunol 2012;2012:494356.
6. Smolen JS, Butcher B, Fritzler MJ, et al. Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting. Arthritis Rheum 1997;40:413-18.
7. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.
8. Bossuyt X. Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory. Autoimmun Rev 2009;8:543-8.
9. Meroni PL, Schur PH. ANA screening: An old test with new recommendations. Ann Rheum Dis 2010;69:1420-2.
10. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997;40:1601-11. (Pubitemid 27426153)
11. Op De Beeck K, Vermeersch P, Verschueren P, et al. Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay. Autoimmun Rev 2011;10:801-8.
12. Satoh M, Chan EK, Ho LA, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 2012; 64:2319-27.
13. Lyons R, Narain S, Nichols C, et al. Effective use of autoantibody tests in the diagnosis of systemic autoimmune disease. Ann N Y Acad Sci 2005;1050:217-28. (Pubitemid 41129439)
14. Fritzler MJ, Rattner JB, Luft LM, et al. Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev 2010.
15. Fritzler MJ, Rattner JB, Luft LM, et al. Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev 2011;10:194-200.
16. Mahler M, Miyachi K, Peebles C, et al. The clinical significance of autoantibodies to the proliferating cell nuclear antigen (PCNA). Autoimmun Rev 2012;11:771-5.
17. Vermeersch P, De Beeck KO, Lauwerys BR, et al. Antinuclear antibodies directed against proliferating cell nuclear antigen are not specifically associated with systemic lupus erythematosus. Ann Rheum Dis 2009;68:1791-3.
18. Schulte-Pelkum J, Fritzler M, Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 2009;8:632-7.
19. Peene I, Meheus L, De KS, et al. Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Ann Rheum Dis 2002;61:929-33.
20. Wiik AS, Hoier-Madsen M, Forslid J, et al. Antinuclear antibodies: A contemporary nomenclature using HEp-2 cells. J Autoimmun 2010;35:276-90.
21. Yazdany J, Schmajuk G, Robbins M, et al. Choosing wisely: The American College of Rheumatology's Top 5 list of things physicians and patients should question. Arthritis Care Res (Hoboken) 2013;65:329-39.
22. Hoffman IE, Peene I, Veys EM, et al. Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests. Clin Chem 2002;48:2171-6. (Pubitemid 35397559)
23. Mahler M, Fritzler MJ. Anti-dsDNA antibody testing in the clinic: Farr or ELISA? Nat Clin Pract Rheumatol 2007;3:72-3.
24. Derksen RH, Bast EJ, Strooisma T, et al. A comparison between the Farr radioimmunoassay and a new automated fluorescence immunoassay for the detection of antibodies against double stranded DNA in serum. Ann Rheum Dis 2002;61:1099-102. (Pubitemid 35397359)
25. Smeenk RJ, van den Brink HG, Brinkman K, et al. Anti-ds DNA: choice of assay in relation to clinical value. Rheumatol Int 1991;11:101-7.
26. Isenberg DA, Dudeney C, Williams W, et al. Measurement of anti-DNA antibodies: A reappraisal using five different methods. Ann Rheum Dis 1987;46:448-56. (Pubitemid 17129917)